ISIlaria Sciamanna

Ilaria Sciamanna

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ilaria Sciamanna has a total of 118 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Reverse transcriptase inhibitors induce autophagy in a LINE-1 ORF1p-dependent manner

    by Michela Damizia, Mirko Baranzini, Ilaria Sciamanna, Ludovica Altieri, Paola Rovella, Omar G. Rosas Bringa, Samira Hozeifi, Leila J. Saba, Apostolos Mourtzinos, Anna O’SHea, et al.

  • Open Access

    Reverse transcriptase inhibitors induce autophagy in a LINE-1 ORF1p-dependent manner

    by Michela Damizia, Mirko Baranzini, Ilaria Sciamanna, Ludovica Altieri, Paola Rovella, Omar G. Rosas Bringa, Samira Hozeifi, Leila J Saba, Apostolos Mourtzinos, Anna O’shea, et al.

    Human L ong Interspersed N uclear E lement-1 (LINE-1) retrotransposons propagate throughout the genome via reverse-transcribed RNA intermediates. LINE-1 expression is pervasive in cancer. Functional LINE-1s encode two proteins: ORF1p, an RNA-binding protein, and ORF2p, harboring reverse transcriptase and endonuclease activities. Reverse transcriptase inhibitors, including non-nucleoside (NNRTI) and nucleoside (NRTI) inhibitors, inhibit cancer cell proliferation and antagonize cancer progression. We previously found that two NNRTIs induced DNA damage, nuclear lamin rupture, micronuclei formation, and autophagy in prostate cancer cells. We now find that two different RTIs up-regulate LINE-1 mRNA expression and ORF1p abundance in nuclei, triggering ORF1p interactions with lamin B1 and with DNA damage factors. ORF1p accumulates within micronuclei with damaged DNA and with the autophagy receptor p62. We further demonstrate that inhibiting autophagy, or decreasing ORF1p levels, prevent DNA damage and preserve lamin B1 integrity, uncoverig a role of LINE-1-ORF1p in the autophagy response of cancer cells, independent on retrotranscription events.

  • Open Access

    An Epigenetic LINE-1-Based Mechanism in Cancer

    by Patrizia Lavia, Ilaria Sciamanna, Corrado Spadafora

    In the last fifty years, large efforts have been deployed in basic research, clinical oncology, and clinical trials, yielding an enormous amount of information regarding the molecular mechanisms of cancer and the design of effective therapies. The knowledge that has accumulated underpins the complexity, multifactoriality, and heterogeneity of cancer, disclosing novel landscapes in cancer biology with a key role of genome plasticity. Here, we propose that cancer onset and progression are determined by a stress-responsive epigenetic mechanism, resulting from the convergence of upregulation of LINE-1 (long interspersed nuclear element 1), the largest family of human retrotransposons, genome damage, nuclear lamina fragmentation, chromatin remodeling, genome reprogramming, and autophagy activation. The upregulated expression of LINE-1 retrotransposons and their protein products plays a key role in these processes, yielding an increased plasticity of the nuclear architecture with the ensuing reprogramming of global gene expression, including the reactivation of embryonic transcription profiles. Cancer phenotypes would thus emerge as a consequence of the unscheduled reactivation of embryonic gene expression patterns in an inappropriate context, triggering de-differentiation and aberrant proliferation in differentiated cells. Depending on the intensity of the stressing stimuli and the level of LINE-1 response, diverse degrees of malignity would be generated.


  • Open Access

    Long interspersed nuclear element-1 expression and retrotransposition in prostate cancer cells

    by Erica M. Briggs, Susan Ha, Paolo Mita, Gregory Brittingham, Ilaria Sciamanna, Corrado Spadafora, Susan K. Logan

    Long Interspersed Nuclear Element-1 (LINE-1) is an autonomous retrotransposon that generates new genomic insertions through the retrotransposition of a RNA intermediate. Expression of LINE-1 is tightly repressed in most somatic tissues to prevent DNA damage and ensure genomic integrity. However, the reactivation of LINE-1 has been documented in cancer and the role of LINE-1 protein expression and retrotransposition has become of interest in the development, progression, and adaptation of many epithelial neoplasms, including prostate cancer. Here, we examined endogenous LINE-1 protein expression and localization in a panel of prostate cancer cells and observed a diverse range of LINE-1 expression patterns between cell lines. Subcellular localization of LINE-1 proteins, ORF1p and ORF2p, revealed distinct expression patterns. ORF1p, a nucleic acid chaperone that binds LINE-1 mRNA, was predominantly expressed in the cytoplasm, with minor localization in the nucleus. ORF2p, containing endonuclease and reverse transcriptase domains, exhibited punctate foci in the nucleus and also displayed co-localization with PCNA and γH2AX. Using a retrotransposition reporter assay, we found variations in LINE-1 retrotransposition between cell lines. Overall, our findings reveal new insight into the expression and retrotransposition of LINE-1 in prostate cancer. The prostate cancer cells we investigated provide a unique model for investigating endogenous LINE-1 activity and provide a functional model for studying LINE-1 mechanisms in prostate cancer.


  • Open Access

    HERV-K activation is strictly required to sustain CD133+ melanoma cells with stemness features

    by Ayele Argaw-Denboba, Emanuela Balestrieri, Annalucia Serafino, Chiara Cipriani, Ilaria Bucci, Roberta Sorrentino, Ilaria Sciamanna, Alessandra Gambacurta, Paola Sinibaldi-Vallebona, Claudia Matteucci

    Melanoma is a heterogeneous tumor in which phenotype-switching and CD133 marker have been associated with metastasis promotion and chemotherapy resistance. CD133 positive (CD133+) subpopulation has also been suggested as putative cancer stem cell (CSC) of melanoma tumor. Human endogenous retrovirus type K (HERV-K) has been described to be aberrantly activated during melanoma progression and implicated in the etiopathogenesis of disease. Earlier, we reported that stress-induced HERV-K activation promotes cell malignant transformation and reduces the immunogenicity of melanoma cells. Herein, we investigated the correlation between HERV-K and the CD133+ melanoma cells during microenvironmental modifications. TVM-A12 cell line, isolated in our laboratory from a primary human melanoma lesion, and other commercial melanoma cell lines (G-361, WM-115, WM-266-4 and A375) were grown and maintained in the standard and stem cell media. RNA interference, Real-time PCR, flow cytometry analysis, self-renewal and migration/invasion assays were performed to characterize cell behavior and HERV-K expression. Melanoma cells, exposed to stem cell media, undergo phenotype-switching and expansion of CD133+ melanoma cells, concomitantly promoted by HERV-K activation. Notably, the sorted CD133+ subpopulation showed stemness features, characterized by higher self-renewal ability, embryonic genes expression, migration and invasion capacities compared to the parental cell line. RNA interference-mediated downregulation experiments showed that HERV-K has a decisive role to expand and maintain the CD133+ melanoma subpopulation during microenvironmental modifications. Similarly, non nucleoside reverse transcriptase inhibitors (NNRTIs) efavirenz and nevirapine were effective to restrain the activation of HERV-K in melanoma cells, to antagonize CD133+ subpopulation expansion and to induce selective high level apoptosis in CD133+ cells. HERV-K activation promotes melanoma cells phenotype-switching and is strictly required to expand and maintain the CD133+ melanoma cells with stemness features in response to microenvironmental modifications.


  • Open Access

    Antitumor effect of combination of the inhibitors of two new oncotargets: proton pumps and reverse transcriptase

    by Luana Lugini, Ilaria Sciamanna, Cristina Federici, Elisabetta Iessi, Enrico Pierluigi Spugnini, Stefano Fais

    Antitumor effect of combination of the inhibitors of two new oncotargets: proton pumps and reverse transcriptase


  • Open Access

    The Reverse Transcriptase Encoded by LINE-1 Retrotransposons in the Genesis, Progression, and Therapy of Cancer

    by Ilaria Sciamanna, Chiara De Luca, Corrado Spadafora

    In higher eukaryotic genomes, Long Interspersed Nuclear Element 1 (LINE-1) retrotransposons represent a large family of repeated genomic elements. They transpose using a reverse transcriptase (RT), which they encode as part of the ORF2p product. RT inhibition in cancer cells, either via RNA interference-dependent silencing of active LINE-1 elements, or using RT inhibitory drugs, reduces cancer cell proliferation, promotes their differentiation and antagonizes tumor progression in animal models. Indeed, the nonnucleoside RT inhibitor efavirenz has recently been tested in a phase II clinical trial with metastatic prostate cancer patients. An in-depth analysis of ORF2p in a mouse model of breast cancer showed ORF2p to be precociously expressed in precancerous lesions and highly abundant in advanced cancer stages, while being barely detectable in normal breast tissue, providing a rationale for the finding that RT-expressing tumours are therapeutically sensitive to RT inhibitors. We summarise mechanistic and gene profiling studies indicating that highly abundant LINE-1-derived RT can “sequester” RNA substrates for reverse transcription in tumor cells, entailing the formation of RNA:DNA hybrid molecules and impairing the overall production of regulatory miRNAs, with a global impact on the cell transcriptome. Based on these data, LINE-1-ORF2 encoded RT has a tumor-promoting potential that is exerted at an epigenetic level. We propose a model whereby LINE1-RT drives a previously unrecognized global regulatory process, the deregulation of which drives cell transformation and tumorigenesis and possibly implicated in cancer cell heterogeneity.


  • Open Access

    Enhanced expression of LINE-1-encoded ORF2 protein in early stages of colon and prostate transformation

    by Chiara De Luca, Fiorella Guadagni, Paola Sinibaldi-Vallebona, Steno Sentinelli, Michele Gallucci, Andreas Hoffmann, Gerald G. Schumann, Corrado Spadafora, Ilaria Sciamanna

    Enhanced expression of LINE-1-encoded ORF2 protein in early stages of colon and prostate transformation


  • Open Access

    Regulatory roles of LINE-1-encoded reverse transcriptase in cancer onset and progression

    by Ilaria Sciamanna, Alberto Gualtieri, Pier Vincenzo Piazza, Corrado Spadafora

    // <![CDATA[ $('.header-date').hide();$('#titleAuthors').hide();$('#abstractHeader').hide(); // ]]> Ilaria Sciamanna 1 , Alberto Gualtieri 1 , Pier Vincenzo Piazza 2 , Corrado Spadafora 1 1 Istituto Superiore di Sanità, Viale Regina Elena 299, Rome, Italy 2 NeuroCentre Magendie, INSERM U862, Univ Bdx2, Bordeaux, France Correspondence to: Corrado Spadafora, e-mail: cspadaf@tin.it Keywords: Retrotransposon, reverse transcriptase, inhibitor, non coding RNA, cancer therapy Received: August 01, 2014 Accepted: September 16, 2014 Published: October 29, 2014 ABSTRACT LINE-1 retrotransposons encode the reverse transcriptase (RT) enzyme, required for their own mobility, the expression of which is inhibited in differentiated tissues while being active in tumors. Experimental evidence indicate that the inhibition of LINE-1-derived RT restores differentiation in cancer cells, inhibits tumor progression and yields globally reprogrammed transcription profiles. Newly emerging data suggest that LINE-1-encoded RT modulates the biogenesis of miRNAs, by governing the balance between the production of regulatory double-stranded RNAs and RNA:DNA hybrid molecules, with a direct impact on global gene expression. Abnormally high RT activity unbalances the transcriptome in cancer cells, while RT inhibition restores ‘normal’ miRNA profiles and their regulatory networks. This RT-dependent mechanism can target the myriad of transcripts - both coding and non-coding, sense and antisense - in eukaryotic transcriptomes, with a profound impact on cell fates. LINE-1-encoded RT emerges therefore as a key regulator of a previously unrecognized mechanism in tumorigenesis


  • Open Access

    A tumor-promoting mechanism mediated by retrotransposon-encoded reverse transcriptase is active in human transformed cell lines

    by Ilaria Sciamanna, Alberto Gualtieri, Cristina Cossetti, Emanuele Felice Osimo, Manuela Ferracin, Gianfranco Macchia, Eleonora Aricò, Gianni Prosseda, Patrizia Vitullo, Tom Misteli, et al.

    LINE-1 elements make up the most abundant retrotransposon family in the human genome. Full-length LINE-1 elements encode a reverse transcriptase (RT) activity required for their own retrotranpsosition as well as that of non-autonomous Alu elements. LINE-1 are poorly expressed in normal cells and abundantly in cancer cells. Decreasing RT activity in cancer cells, by either LINE-1-specific RNA interference, or by RT inhibitory drugs, was previously found to reduce proliferation and promote differentiation and to antagonize tumor growth in animal models. Here we have investigated how RT exerts these global regulatory functions.